Earnings Call: Q1 2021

Apr 30, 2021

As a reminder, this call is being recorded. Please proceed. Good morning, and welcome to Acadia's Q1 2021 conference call. I'm Gretchen Hamerick, Director of Investor Relations for Acadia. I'll first provide you with our safe harbor before turning the call over to our Chief Executive Officer, Debbie Osteen. To the extent any non GAAP financial measure is discussed in today's call, you will also find a reconciliation of that measure to the most directly comparable financial measure calculated according to GAAP on our website by viewing yesterday's news release under the Investors link. This conference call may contain forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements, among others, regarding Acadia's expected quarterly and annual financial performance for 2021 and beyond. For this purpose, any statements made during this call that are not statements of historical fact may be deemed to be forward looking statements. Without limiting the foregoing, the words believes, anticipates, plans, expects and similar expressions are intended to identify forward looking statements. You are hereby cautioned that these statements may by the important factors among others set forth in Acadia's filings with the Securities and Exchange Commission and in the company's Q1 news release. And consequently, actual operations and results may differ materially from the results discussed in the forward looking statements. The company undertakes no obligation to update publicly any forward looking statements whether as a result of new information, future events or otherwise. At this time, for opening remarks, I would like to turn the conference call over to Chief Executive Officer, Debbie Osteen. Good morning and thank you for being with us today for our Q1 2021 conference call. I'm here today with Chief Financial Officer, David Duckworth Duckworth and other members of our executive management team. David and I will provide some remarks about our financial and operating results for the Q1 of 2021 and guidance for 2021. Following David's comments, we will open the line for your questions. We are very pleased with our solid financial and operating performance for the Q1, marking a strong start to 2021. These results demonstrate consistent and successful execution of our growth strategy as well as strong cost management in the face of the impact from the resurgence of COVID and one less day in 2021 due to leap year in 2020. Before we get into the results, I want to commend Acadia's dedicated employees and clinicians across our operations who have continued to meet this critical demand and provide the highest quality care in a safe and accessible manner. We have a proven operating model supported by an experienced team as well as the financial strength to support our ability to reach more patients who need our services. For the Q1 of 2021, our U. S. Operations produced very favorable results, driven by solid volumes and strong cost management. Our same facility revenue increased 7.4% compared with the Q1 of 2020, including a 2.7% increase in patient days and a 4.5% increase in revenue per patient day. Acadia is well positioned to meet the needs of those seeking behavioral treatment with our diversified service lines, all of which provide high levels of exceptional patient care. In 2021 beyond, we believe that there will be continued growth in demand for all these services. While we are beginning to see some relief from the pandemic with increased vaccinations and a less restrictive environment, elevated levels of mental health and substance use disorders are expected to remain long after the COVID-nineteen pandemic ends. A recent study from Kaiser finds that about half of adults continue to report negative mental health issues related to worry or stress from the pandemic. And we are prepared to help these individuals get the treatment they need. We are also seeing higher demand as societal acceptance of behavioral health increases and coverage options for those seeking treatment expand and improve. I would like to highlight a couple of trends in the quarter. Overall, we continue to see strong demand in the first quarter and have seen the demand continue into April. While there was some resurgence of COVID-nineteen that followed the holidays, as always our facility management teams and clinicians did a great job in addressing this challenge by strictly adhering to safety protocols and processes and working in collaboration with local health departments. Through consistent and open communication, we were able to operate effectively and meet the needs of our patients. Our specialty business which focuses on inpatient residential programs has been slower to rebound following the initial impact from the pandemic, but we were encouraged by the strong trends in this service line as the quarter progressed. As more people are willing to travel, vaccination rates increase and restrictions are lifted, We are seeing higher admissions in these facilities. On our Q4 2020 call, we shared with investors our growth strategy going forward with our singular focus now on our U. S. Operations. We identified 4 distinct growth pathways that we believe will provide additional opportunities for Acadia to reach more patients in new and existing markets. I am pleased with our progress so far this year in each of these initiatives. As we continue to make investments in key strategic areas that will support our long term growth across our service lines. First, facility expansions remain a primary focus of our growth strategy. And accordingly, we added 92 beds to our existing U. S. Operations in the Q1. As previously announced, we plan to add approximately 300 beds this year to meet the growing demand in our current markets. We also continued to identify underserved markets for behavioral health treatment, especially for treatment of patients with opioid use disorder. As I noted earlier, in addition to the many challenges presented by COVID-nineteen, recent studies have shown that the pandemic has continued to affect mental health, including a resurgence in opioid use in the wake of widespread unemployment and isolation. New data also shows that more Americans died of drug overdoses in the year leading up to September 2020 than any 12 month period since the opioid epidemic began. To address this critical and growing need, we opened 2 new CTCs in the Q1 of 2021. CTCs operate on an outpatient basis and combine behavioral therapy and medication to achieve long term recovery from opioid use disorder. We continue to see opportunities to help more individuals struggling with addiction and we are on track to open 11 new CTCs in 2021. 2nd, following the end of the quarter, we executed on another priority for our continued growth by completing construction of a de novo facility, Glenwood Behavioral Health, an 80 bed hospital in Cincinnati, Ohio. This facility will provide inpatient psychiatric treatment for those who are struggling with a mental health or substance use disorder. We expect this facility to be fully operational during the Q2 of 2021. 3rd, establishing joint venture partnerships with healthcare delivery systems across the country has been another important growth initiative for Acadia. And we have been fortunate to partner with many leading providers in attractive markets. In March, we were pleased to announce a joint venture with Lutheran Health Network of Indiana, one of Indiana's premier integrated healthcare delivery systems. Together, we plan to build a new 120 bed behavioral health hospital serving Fort Wayne and the surrounding counties. The new hospital slated to open in spring 2022 will provide a full continuum of inpatient and outpatient care services. We also announced a joint venture with Geisinger Health, one of Pennsylvania's premier integrated healthcare systems. The new partnership will build 2 new 96 Bed behavioral health facilities providing comprehensive inpatient services in the central and northeastern regions of the state. The first facility is expected to open in 2022 and the second in 2023. Both the Lutheran Health and Geisinger Health partnerships will leverage our combined expertise and resources with a shared commitment to provide quality care and achieve strong clinical outcomes. We will continue to pursue this important pathway of growth for Acadia in the year ahead and beyond. With a solid pipeline of joint venture projects in different stages, we expect 2022 to be our strongest year for joint ventures with 4 to 5 facilities expected to open. Finally, another important pathway to growth is through acquisitions. Acquisitions have been an important part of Acadia's growth strategy and the fragmented behavioral healthcare industry provides ample opportunity for future acquisitions. During the Q1, we signed a definitive agreement to acquire Vallejo Behavioral, a 61 bed psychiatric hospital in Vallejo, California from Adventist Health. We are excited to add this facility to our portfolio and we will continue to identify additional acquisitions that meet our criteria. We believe there are significant opportunities for growth for Acadia as we continue to expand our market reach through bed expansions, wholly owned de novo facilities, strategic joint ventures and acquisitions. Importantly, our balance sheet is very strong with ample capital to pursue these growth initiatives and also continue to make strategic investments in our business. Now, I will turn the call over to David Duckworth to discuss our financial results in more detail. Thanks Debbie and good morning. Revenue from our continuing operations for the Q1 was $551,200,000 compared with $509,200,000 for the Q1 of 2020, a growth rate of 8.2%. Net income attributable to Acadia stockholders was $9,700,000 or $0.11 per diluted share. Adjusted income from continuing operations attributable to Acadia stockholders per diluted share was 0 point 4 $7 for the Q1 of 2021. Adjusted excludes income from discontinued operations as well as a $1,700,000 tax benefit related to ASU 20 sixteen-nine transaction related expenses, debt extinguishment cost and the income tax effect of these adjustments to income. Acadia's continuing operations adjusted EBITDA for the first quarter of 2021 was $119,500,000 compared with $96,700,000 for the same period last year. Same facility adjusted EBITDA margin improved 280 basis points to 26.5%. In March 2021, the company completed its expected debt repayment and refinancing plans following the completion of the UK sale in January. We have strengthened our capital structure through the reduction in debt totaling $1,600,000,000 in the Q1 of 2021 as well as the refinancing transactions completed in 2020 and in the Q1 this year. With the completion of these transactions, Acadia's debt structure includes the new $1,025,000,000 revolving credit and term loan facilities, dollars 450,000,000 of 5.5 percent senior notes due 2028 and $475,000,000 of 5 percent senior notes due 2029. The company's net leverage ratio was approximately 2.7 times as of March 31, 2021. Cash at the end of the Q1 was $179,000,000 and we have $160,000,000 drawn on our new revolving line of credit of $600,000,000 Turning to our financial guidance, as noted in our press release, we have increased the previous financial guidance for 2021 as follows: revenue in a range of $2,240,000,000 to $2,290,000,000 adjusted EBITDA in a range of $500,000,000 to $530,000,000 and adjusted earnings per diluted share in a range of $2.30 to $2.55 With the completion of our debt refinancings in March, our interest expense for the remainder of 2021 is expected to be approximately $17,000,000 per quarter. With our improved debt structure, our ongoing cost management initiatives and our disciplined capital allocation, we have a solid financial position to support our business. We will continue to make strategic investments in the business while aligning our costs to meet the ongoing needs of our patients. We are confident that the essential nature of the services we provide supported by robust demand will lead to growth through 2021 and beyond. With that, Christina, we are ready to open the call for questions. We'll take our first question from Frank Morgan with RBC Capital Markets. Good morning. First question on the strong same store top line growth. Just curious when I look at that, looks like nice growth in patient days and part of that driven by about 2% growth in length of stay. So I'm just curious what's driving that increase? And then any color or any breakout on the 4.5 percent on the pricing side? And then second question is on just the margins and the sustainability there. Obviously, you've had some really good cost initiatives in place, things like purchasing, but any other remaining areas of focus we should look for there, even including labor? Thanks. I'll take the first part of that, Frank. I think when we look at our volume trends for the Q1, our acute census continues to be just very stable and strong. I think that what we were pleased with is that our specialty census, which had a slower ramp up during last year, during the pandemic and also had a little bit of a slowness after the holidays, we started to see some very strong trends for specialty. I think that if we look at year over year growth both in February March, we were very pleased with that growth in the specialty area. I think that what we're seeing there is that travel is starting to return to normal. I think that we've also seen an increase in our out of state admissions and our volumes there. We actually had the highest referrals from out of state, referrals that we've seen since January of 2020. We always had, I think, consistent performance even during the pandemic from our RTC and our CTC service line. But those trends are also very strong and have continued, as I said in my remarks, into April. I think David, if you want to add to that. And Frank picking up on the revenue per day, we did see a strong revenue per day of 4.5% year over year growth here in the Q1. That is a continuation of a strong trend that we have seen. We were above 3% in the second half of twenty twenty. Our team at the facility and the corporate and those that manage our payer relationships here at the corporate office are doing a great job on rate increases across our service lines. And in Q1, we're also seeing a strong payer mix. Our commercial payer mix did increase slightly, just under 30% for the quarter. That is a contributing factor to our revenue per day growth being at 4.5% and part of that does relate to the specialty facilities and the volumes we saw there at some of the higher revenue per day specialty facilities where we're now seeing strong volumes as we exit the quarter. That is a contributing factor to that strong revenue per day number for the quarter and that's a trend that we see continuing into April and continuing into the year. I'll just add Frank on the margin. I think that we had very good cost management and I have to give the operations team just a lot of credit. They stayed very focused on that area. And I think we've been able to sustain the savings from our initiatives in that we identified in 2019, but we've also achieved other efficiencies and cost adjustments in 2020 that continued into 2021. We are looking for additional opportunities for savings, But as I just look at their efforts in the Q1, our margin had a very good impact from that cost management, but then also as David mentioned, our strong revenue per day. So those two things combined I think helped us and that's why we saw the improvement in the margin. And we believe that we're in a strong position to carry those efforts forward and we believe that the margin can be sustained and we're hoping to improve it from where we are right now. Thanks very much. We'll take our next question from Kevin Fischbeck with Bank of America. Okay, great. Thanks. I guess wanted to hear your view on M and A. I guess there's a couple of large transactions out there. Love to hear your thoughts. You mentioned your balance sheet strength. Where do you think you'd be willing to take your balance sheet for the right transaction going forward? We do see capacity with our balance sheet and our leverage being at 2.7 relative to a longer term range that we're thinking of for our now U. S. Only business of 3 to 4. We are not in a hurry to take the leverage to the high end of that range, but do think for the right opportunity that that is the situation where we would be at the higher end of the range. But any M and A transactions that we evaluate, we're evaluating through our framework that we have established that we think will serve us well, thinking of the strategic fit, the markets, the real estate, many other factors related to the specific acquisition that we look at and of course financial returns and Acadia specific factors. So we'll continue to look at M and A opportunities using the criteria and the framework we have. And for the right transaction, we would think about the right place to be within the leverage range. But we're certainly pleased that we not only have that capacity, but we also have multiple options as we think about our growth and the 4th growth pathways that we talked about earlier, I think M and A is part of that. But there's also other options and multiple ways that we think we will continue to see those growth opportunities. Okay. And then just I guess we think about the de novo growth, is there anything we should be thinking about or being prepared for? I guess in the past sometimes when you open up a new facility it has startup losses for some period of time. If you guys are doing more JV developments next year than you have in a long time. Is there anything to think about from a margin perspective? We have talked about in the 1st year of operations for a new facility incurring losses that we estimate around $2,000,000 We have 4 facilities right now in various stages of that startup process with 2 facilities opening in the second half of last year and 2 more that are opening at various points in time this year. So we do think that we can manage that number. That should be a fairly consistent number. Of course, if we think about next year, potentially higher number of new facilities, we could see just a greater overall number. It's just going to depend on the timing of those transactions. What we have seen though with the transactions we opened last year that I think we have the facility that has been fastest to breaking even. As we look back at the history of the company with the one that we opened in the Q3 last year being breakeven here in its Q3 of operations. So I think part of that is the team that we have just doing a fantastic job opening that new facility, but also just the benefit of having a joint venture partner as we open a new facility in certain markets. We're seeing a faster ramp than what we've seen in the past. So there is a $2,000,000 or so investment in those startup losses, but at the same time, we are doing a great job getting those new facilities open and hope for a very successful year as we think about a greater number of those new facilities next year. And Kevin, I'll just add to what David said. I think he mentioned the joint venture that we opened in the summer with Tower. And I think what we've seen there is what we're seeing really across the company and that is strong demand. We've had very solid pricing and good execution by the team on the ground to really get the facility open. We've just been very pleased. We are looking at opening even more services there in the next month or so. So I think this is a growth pathway with integration as well as the de novos that we think while there is the short term impact, the long term of both of those strategies we feel are very positive for us. And there are a number of markets that we think are underserved in the de novo area in particular that we've identified and we think that we have a good pathway there as well as to the integrations. All right. Thanks. Our next question is from Ralph Giacobbe with Citi. Thanks. Good morning. Debbie, you mentioned out of state referrals. I guess are there incremental referral streams you're seeing as well? Do you think you're just capturing greater share than maybe previously? And then any other strategies particularly as we think about sort of more usage of telehealth in the behavioral space from a referral standpoint? Well, Ralph, I think if we think about the facilities, the specialty facilities, they pull from a wide range really across the country. And I think that during the pandemic, we did see those referrals were impacted because for the most part, unless it's close to the state where our services are, individuals do fly and travel in that manner. So as we are looking at it for the Q1, what we've seen is that there's more comfort in traveling. And so these referral sources have really been with us for a number of years. They're very stable and steady. I think now what we've seen is just we've been able to accommodate those referrals and they've been able to make their way to our facilities. We do have programs that we've opened in several of our specialty facilities that are more specialized. So I do think we're getting in new patients as well as new referral sources that have in a lot of cases asked us to provide those services. So I do think there is additional referrals that are coming, but then we've seen a return of those that have been steady over a number of years. And we have an excellent track record and reputation. So now that I think some of the pandemic and vaccinations are those are happening. I think we're going to continue to see our specialty census not only recover, but build from where we are right now. We've certainly seen that in April as well. Okay. And then what about on the telehealth side in terms of referral patterns and relationships with some of those providers? We have through telehealth, we really utilize that for our outpatient services. And during the pandemic, it was used to access our services. But I think that certainly through telehealth, it's really an access way for our patients to avail themselves of our services. So if we're in a rural area or even we are planning to try and expand telehealth in some of our acute and specialty service areas where if someone is coming from a distance, we can then extend the continuum and use telehealth as a way for them to continue their treatment with us. And I think that our referral sources during the pandemic and to some extent even as we're seeing that start to become less of an impact to us, our referral sources and our physicians for that matter are comfortable with telehealth. They are using it. And I think that it just opens up a new area of opportunity for us. That's one of the positive things I think that occurred from the pandemic is we are looking at support for our existing services. We are looking at ways to expand the existing services and that's connecting with not only referral sources, but our patients. And then also we're looking at growth into new service areas and that might be linking with someone that is providing those telehealth services either a physician group or others that we might partner with. Okay. That's helpful. And then just quickly a follow-up. I want to go back to the cost Just wondering if there's anything more to sort of call out there. I guess what I'm trying to reconcile is you put up 7% same store revenue against 20% same facility EBITDA growth, right? So obviously you mentioned sort of balance of pricing as well as sort of the sustainability of margins. So I'm just trying to reconcile and understand, do you need the pricing levels to sustain these margin levels? Or if there's a way to sort of frame the benefit of sort of the pricing drop through the margins relative to the sustainability of some of the cost initiatives? Thanks. Sure. We do think that virtually all the margin improvement is related to the cost management initiatives. And I know we've talked about those over the last 2 years and all the tools that have been put in place to manage our costs, the cost savings initiatives that we talked about and implemented last year, we do see those as the primary drivers of where our margin was for the Q1. And really a good way to think about that is if you look at the second half of twenty twenty, we were 27%, 28% margin and that was sustained into the Q1. We do see some seasonality in the Q1 related to payroll taxes and the calendar around the payroll taxes that has about a 1% impact on margin. So if you think about where we were trending in the second half of last year, that is being sustained into the Q1 with the exception of that seasonality. And so that's probably a more helpful way to think about the margin. And of course, on a year over year basis, it does reflect a higher level of margin growth because of some of those cost savings that were implemented throughout 2020. Got it. Okay. Thank you. We'll take our next question from A. J. Rice with Credit Suisse. Hi, everybody. First, maybe just on the guidance raise $10,000,000 on both sides of the range. Is that purely just to confirm the Q1 outperformance? I don't know where you were relative to your own expectations. I know you're about $7,000,000 ahead of consensus. And then the sequestration with the back half operationally in your view remaining unchanged. And is there anything about the Q1 outperformance that wouldn't continue into the rest of the year? Is it just too early to maybe make a change in the outlook? But nothing in the back half that's somehow gotten a little worse? The main factors behind our increase in the guidance were the 1st quarter beat and it was around $7,000,000 ahead of our expectations as represented by the midpoint of our Q1 guidance range, which was $110,000,000 to $115,000,000 So there is around $7,000,000 there. Medicare sequestration and the extension through the end of the year is $3,500,000 value to us. We have about 11% of our revenue is with Medicare. There's another 5% or so that is with the managed Medicare payer, but that sequestration is related to around 11% of our revenue and there's a $3,500,000 value there from April to December. The other there's no other changes in our guidance. I think our guidance as we entered the year already reflected continuing strong trends in our volume and in our margin. And so with the trends we're seeing in April, part of our reaffirming and increasing our guidance is that we do see those trends that were part of our original guidance now continuing for the year as we are seeing in April. And A. J, there's nothing else that we saw in the Q1 or see in the year that we believe we need to call out. Those are the primary drivers of our increase. Okay. That's great. And let me just say on the follow-up, obviously, you got the uptick in JVs as you think about heading into next year. You're expressing openness on M and A tuck in potentially larger deals too I guess. What is the competitive landscape look like? It seems like some of the private equity guys that were competing with you for transactions may actually be now sellers. Is the competitive landscape getting a little better and maybe that's part of the reason we're seeing the uptick in JVs or is it about the same? And has anything changed in the way you're seeing people pricing deals? It's hard for us to know exactly what the competitive landscape is And I know there may be private equity that sellers, but there may also be buyers within the same space. And there does seem to be acquisition opportunities right now, but it's hard for us to really have a view on either the competition for that or the pricing. We'll see. I don't think we have as many data points to look at just looking back on the last several years. So we don't have a view right now really on either the competition or the pricing. We, of course, as we think about our own framework, feel like we have the right way to think about acquisitions as well as those other opportunities. And so we'll use that criteria as we evaluate opportunities and we'll see. And I'll just say, A. J, I think that our diversity of service lines gives us multiple opportunities for certainly M and A, not just in our acute space and service lines, but also the specialty in the CTC area. I do think that we're well informed of the market. We, as David said, can't really speak about the competition there. But I think that as we look forward, we think there's going to be opportunity. There are, I believe, companies that may not have fared well through the pandemic. And if there's a way that we can look at those and they are attractive to us from a strategic and financial fit, we will pursue those. But we also want to, as David said, keep a disciplined approach with our balance sheet giving us really a lot of flexibility. And I think that that's why we feel that's going to be an important pathway. But we'll have to see how pricing looks and how it fits in our view of return on invested capital and other things that we are going to be disciplined about. Okay. Thanks a lot. Yes. We'll go to our next question from Brian Delet with Jefferies. Hey, good morning guys. Congratulations. I guess just trying to go back to Frank's question earlier. So, Debbie, if I think about this, you're saying that we've seen some strength carrying over into April. So as I look at the admission trend from Q1, I think it was up 80 basis points. And then the pickup in average month of stay and I think you've talked a lot about how specialty is pretty strong. Is that the right way to think that these numbers should continue to firm up? And theoretically that there's even further acceleration in the organic growth outlook for the back half of the year? I think Brian that's a good way to look at it. I think that as we saw the quarter and the progression and then now we have visibility on April, I think that it's a good assumption that our trends are stronger. And I think that we feel like there's no reason why those would not continue through the rest of the year. With the demand and just again with the pandemic becoming less of an issue, still have a few markets where there are issues with the pandemic, but overall we feel good about just the progression. And also as we just saw March April numbers, we think they're strong. Got it. And then obviously a lot of focus on big deals, but I think with your balance sheet being clean and focused now on the U. S. Only, how are you thinking about the opportunity for tuck ins? Kind of going back to the Acadia of old where you're doing a few tuck ins here and there every quarter? We do believe there will be tuck in acquisition opportunities. We do like those opportunities and we're excited about the one we talked about earlier in California. And so we continue to look for those and believe we will see more of those and they do present a very good opportunity for us and the benefit we can bring to that local hospital through the infrastructure and all the initiatives that we've implemented make those acquisition opportunities more attractive. And I'll just say, I think that one in particular Vallejo with Adventist Health Selling, we believe that we will have opportunity to add additional beds just based on what we see with their volume trends. But also we have other facilities in the area and we think they can work together to serve the patients. And so it's got a strategic focus to it, but also a way for us to grow over and above what we're purchasing at this point. Awesome. Thank you. Take our next question from Pito Chickering with Deutsche Bank. Good morning. Thanks for letting me ask some questions. Can you help me understand the dynamics between same store missions and length of stay? When I look at the length of stay increase, it was a primary driver of patient day growth. So the question is, if the growth of length of stay is from managed care easing restrictions or is it an increase in mix from specialty And if managed care starts to push back on length of stay again, do you think you can offset that pressure with increased admissions to keep the patient days growing in the 3% range? We do not view any of our metrics as relating to a change in what managed care is doing. It's been a pretty consistent process pre pandemic and through the last year. We attribute our stats more to just the service mix that we see. We do see a pretty consistent length of stay, but we have to look at it by service line and by facility and it can vary, but it tends to be within a range and we've seen it trend consistently within a range. And Pito, as you ask about admissions, we are seeing a number of factors that impacted our admissions during the quarter and we talked about just coming off of the COVID resurgence and the holidays and seeing a lower admissions, but then seeing a significant progression throughout the quarter in the admissions and in our patient day metrics. And so going forward, we do think that there may be a more similar relationship between admissions and patient days. But again, it can be impacted by the service mix that we see. But with what we saw in March, we are seeing nice admissions growth and we're seeing that into April. Okay, great. And then to follow-up on Ralph's question on the revenue per patient a day growth, It sounds like this growth with mix of specialty and commercial mix is sustainable over 2021. As you mentioned that specialty continues to ramp sort of during March April. Shouldn't the revenue per day increase from these levels? And then on the margin side, if revenue per day continues to increase because of commercial mix and specialty, wouldn't that provide substantial margin leverage beyond what you're able to achieve in the Q1? We do think it will be a continuing factor as we move through the year. Of course, in the second quarter, we'll be comparing back to the quarter that saw the most impact from COVID for the company last year. The second half of twenty twenty, we saw very solid recovery in performance. So the comparison will be different in the second half of this year compared to the Q2. But we do expect to continue to see that dynamic in our revenue per day and to see strong revenue per day trends, especially in the Q2, where we did see a greater impact, like I said, in 2020. So yes, we do expect that trend to continue. Great. Thanks so much and a great quarter, guys. Thank you. We'll go to our next question from John Ransom with Raymond James. Good morning. Just to hit on labor for a minute, I'm curious kind of where your metrics stand now versus say the peak of the pandemic in terms of temps? How many of your folks have been vaccinated turnover? Anything like that would be helpful. Thanks. Well, John, as I think you know, we're located in 40 states. So we will have staffing challenges. They're fairly isolated. I think overall, we've been able to accommodate the demand with our current staff. We've actually seen an improvement in agency from year to year and it's always been very low before that. I think as we look at our process here, we try and be proactive and that started and it was in place before the pandemic. So our team is supporting the facilities. We have a team here, a recruiting team. We also have, I think, some very robust local efforts. And we have used overtime when we need it. But we've also, I think, just generally been able to handle our patients that are coming to us and making sure we can offer services to them. We have, I think, some good initiatives around retention, which I think is very important. So we can recruit and we have some strong support there, but we also have, I think, some good focus around retention of our staff just generally across the company. I think we are continuing to see our employees avail themselves of the vaccine. I think that we're trying to really be very supportive in with our education about the importance of the vaccine. And certainly, it varies by part of the country, but we feel good about our employees and their interest, but also we want to make sure we're educating them about the various vaccines. And also we have a partnership with Walgreens where we are using them as a provider of the vaccine and we also have health departments in many of our areas that have come to our facilities and provided it. So I think that's continuing to increase. And again, we're just pleased that it's something that I think across the country is going to be certainly a positive for all of us, but also for just those that need our services and didn't feel comfortable before. Now that they're vaccinated, we'll seek our services out. Great. Thanks so much. Thank you. And we'll go next to Matt Borsch with BMO Capital Markets. Yes. Hi. Could you just talk about how you're thinking about demand post pandemic. I guess my question is, given the increase in instances of mental health issues during the pandemic. To what extent I know you can't really predict this entirely, but to what extent do you think those will be sustained versus sort of stating once things get back to normal? Well, I think there's 2 parts to this. And one is before the pandemic, 1 in 5 Americans already had a diagnosed mental health condition. So that was before the pandemic. And I think one of the positives that has occurred during the focus on pandemic, it's not just the public health crisis, but the mental health crisis, which you've just mentioned. But I think the other part is that people are more accepting of seeking treatment. So I think we have this need that was there before the pandemic, certainly some increase from just the stress and the isolation. But also, I believe stigma has it's not totally reduced, but I think it's starting to reduce from the levels that I've seen over my career. And I think that we're going to see more people being willing to seek help. And I think that is going to continue. And unfortunately, I do think that this is not a short term issue. There is research from other pandemics that have shown that it really is a long lasting effect. We're ready to offer our services for those that might have PTSD, healthcare workers. I can think of a lot of individuals, certainly adolescents, there's been a lot of research about just the impact on children and adolescents with their mental health worsened. So if I think about it as where the demand trends in general, we started out with strong demand. It's now increased, but we also have more acceptance. And I think this pandemic is going to have long lasting effects. Yes, that makes sense. Thank you. Thank you. There are no further questions at this time. I'd like to turn the call back to Debbie Osteen for any additional or closing remarks. Thank you. Well, I want to thank everyone for being with us today and also for your interest in Acadia Healthcare. I am very grateful to our field and corporate leaders for their resiliency and their commitment to keeping our key growth and operational initiatives moving forward and at the same time responding to this unprecedented crisis. Together, we look forward to the opportunities ahead for Acadia. If you have additional questions today, please do not hesitate to contact us directly and have a good day.